CN106063931A - A kind of for treating wound pruritus and promoting the compositions of wound healing - Google Patents
A kind of for treating wound pruritus and promoting the compositions of wound healing Download PDFInfo
- Publication number
- CN106063931A CN106063931A CN201610585383.2A CN201610585383A CN106063931A CN 106063931 A CN106063931 A CN 106063931A CN 201610585383 A CN201610585383 A CN 201610585383A CN 106063931 A CN106063931 A CN 106063931A
- Authority
- CN
- China
- Prior art keywords
- acid
- glycerol
- compositions
- amylase
- ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a kind of for treating wound pruritus and promoting the compositions of wound healing.Specifically, it is a kind of medical dressing, belongs to biomedicine technical field.Compositions disclosed in this invention is based on amylase, including α, beta, gamma amylase.Described diastatic action is in the α glycosidic bond of polysaccharide so that it is cracking produces the carbohydrate/bglii fragment of low-molecular-weight.By this mechanism, it has further been found that amylase can effectively be alleviated, eliminate skin pruritus, thus reaches to promote the function of wound healing.
Description
Technical field
The present invention discloses a kind of for treating wound pruritus and promoting the compositions of wound healing.Specifically, it is one
Plant medical dressing, belong to biomedicine technical field.
Background technology
Pruritus is a kind of symptom topically or systemically, and what this often led to scratches and stimulate teleneuron.Serious scratches
Grab, chafing, hemorrhage and infection may be caused.Although pruritus usually occurs in skin part, it is it can also happen that at non-skin
Skin position, such as mucosa or cornea.Many reasons is had to cause skin pruritus, including outside and external factor, local skin disease
Disease and systemic disease.Wound or wound healing after operation often accompany local pruritus.Pruritus can also be a composition portion of inflammation
Point.
Although histamine is modal cause itches one of material, but other chemical substance the most also can cause pruritus, such as
Interleukin, prostaglandin etc..Therefore, antihistaminic is it cannot be guaranteed that treat pruritus completely.
At present, how existing various reports treat pruritus card, including non-specific external preparation, such as skin moistening
Agent and counterirritant；Medicine such as corticosteroid；Analeptic, cannabinoid, local anesthetic, hydryllin, anticonvulsant, anti-
Depressant drug, and micro-opiate receptor antagonist；By physics mode, such as light exposure treatment based on UV, cold compress, transcutaneous electrical nerve stings
Swash, and acupuncture.Under conditions of the specific cause of disease, these treatments are effective, and other therapeutic modality is not found to have bright
Aobvious benefit.
In the report of some treatment pruritus cards and promotion wound healing, have been directed to local and use containing proteolytic enzyme
Compositions is treated.As in United States Patent (USP) 3003917, it is used for promoting that the compositions of wound healing includes relaxin,
Proteolytic enzyme, and amylase.Relaxin is a kind of protein hormones belonging to insulin family.It can be in this compositions
The proteolytic enzyme used is trypsin, Chymotrypsin, pepsin, papain, bromelain, ficin
Enzyme and the mixture of proteolytic enzyme extracted from antibacterial.Spendable amylolytic enzyme is bacterial amylase, pancreas or α-shallow lake
Powder enzyme, the mixture of beta amylase.For promoting that the particularly effective compositions of wound healing includes relaxin, trypsin, and
Pancreatic amylase, its each wt compare 5:1:1.
In international monopoly WO 1984/002846, describe the topical ointment of a kind of wound for skin surface, its
Including the papain of promotion wound healing, bromelain, trypsin, chymase, pancreatin, lipase, form sediment
Powder enzyme, Aloe extract etc., there is the mixture of multiple protease.This ointment can reduce the inflammation of skin surface wound and increase
The normal anti-inflammatory activity of strong man's body.
In International Patent Publication No. WO 2010/004367, describe a kind of for treating pruritus and alleviating its symptom
Compositions, comprises superoxide dismutase and catalase..
Summary of the invention
The compositions of the present invention contains α-amylase.All of amylase (α-, β-, gamma amylase) selective hydrolysis polysaccharide
α-glycosidic bond, produce low-molecular-weight carbohydrate/bglii fragment.α-amylase is the preferred enzyme of the present invention.Alphalise starch
The advantage of enzyme includes that it is naturally occurring in the mankind and other mammals, the most also can find in antibacterial and fungus plant.
Although α-amylase is main anti-using α-(Isosorbide-5-Nitrae) glycosidic bond of catalysis hydrolyzation of glucose polymeric inner as it
Should, α-amylase simultaneously, particularly saccharogenic amylase, transfer reaction can be catalyzed.Glucoside residue can be transferred to by α-amylase
In the alcohol of low-molecular-weight or water, this character relates to the transglycosylation activity of glycosidase.There is presently no research to confirm to turn
Whether glycosyl effect is for treatment pruritus or alleviate wound inflammation and have positive role.
Although there being the research much about α-amylase, but the effect of its treatment wound pruritus card not yet has report
Road.A kind of compositions treating pruritus is found that.Use is done by the local of alpha amylase: catalysis α-
(Isosorbide-5-Nitrae) hydrolysis of glycoside bond becomes low molecular weight sugar, to reduce the generation of skin irritation and inflammation.
Before about using multienzyme to promote, in the research of wound healing, mainly to select the thing of carbohydrate activity enzyme
Matter, such as chondroitinase；But it only can catalytic degradation chrondroitin.But it is limited to by wound type, it is impossible to all of wound its
Left and right.In actual clinical work, it is badly in need of a kind of compositions that can be widely applied for all wounds.
As herein described compositions and method are directed to use with non-protein enzyme hydrolysis enzyme for treating what pruritus and its produced
Stimulate and inflammation, particularly α-amylase are to improve this situation.The diastatic hydrolysis of alpha amylase, beta amylase, and γ
The one of enzyme.Particularly α-amylase.It is two kinds of main Types in human body: ptyalin and pancreatic amylase.Saliva, saliva
Liquid amylase is responsible for becoming starch with glycogenolysis glucose, maltose and dextrin.Pancreatic amylase is degraded Digestive further
Starch in system.
Relative to the amylase of three kinds of forms, α-amylase (also referred to as Isosorbide-5-Nitrae-α-D-glucosan glucan hydrolase) is one
Plant the endogenous amylase being present in organism.Its catalyzing hydrolysis has the α-starch of (Isosorbide-5-Nitrae)-glycosidic bond, polysaccharide and oligosaccharide,
Finally produce glucose, maltose and oligosaccharide.These products are not present in the skin of the mankind.Meanwhile, α-amylase
Can't catalytically hydrolyzing alpha-(1,6)-glycosidic bond.
Calcium ion and chloride ion are the principal elements affecting alpha-amylase activity.When calcium ion is combined with enzyme molecule closely
Time, the correct conformation beneficially to hydrolysing activity can be formed.And chloride ion is considered as native activating dose of enzyme.The calcium energy of excess
Enough increase the heat stability of α-amylase.The optimum temperature range of catalysis activity is 40 ° of C～45 ° of C, pH are between 7～7.5.
Amylase (α-, β-, gamma amylase) the α glycosidic bond of selective hydrolysis polysaccharide, produce the carbon hydrate of low-molecular-weight
Thing/bglii fragment.In some embodiments, α-amylase is as all or part of amylase.α-shallow lake selected by the present invention
The notable benefit of powder enzyme is, it naturally occurs in the mankind and other mammals, and it is also in plant, antibacterial and fungus
Find.The amylase of microbial source is generally preferable for commercial use, because it generally produces less expensive, activity is more controlled, former
The supply of material is reliable.Compared to the amylase of microbial source, the amylase in plant and animal source may comprise more to be had
Pest matter, such as phenolic compound (plant), endogenous enzyme inhibitor and protease.
Amylase not self-digestion in water, protein versus hydrolytic enzyme is more stable under identical aqueous conditions.Therefore, can make
Must be stable containing diastatic water formulation.After using, can wash from skin very easily.
The compositions of the present invention can be configured to liquid, gel, powder, paste, ointment, lotion, serosity, emulsion or microemulsion
Liquid.Final product form can be liquid, gel, hydrogel, foam, spray, dressing, mesh sheet, binder, or film, and it can contain
There are film forming polymer, or non-degradable base material, such as a dressing, binder, adhesive tape or foamed materials.The compositions of the present invention is permissible
Including one or more biologically acceptable carrier compatible with described compositions, include but not limited to: water, normal saline
(isotonic saline solution), phosphate buffered saline (PBS) (DPBS or PBS), the saline solution of chloride containing calcium, Ringer's mixture, buffer, glycerol,
Propylene glycol, ethanol, isopropanol, butane-1,3-glycol, Polyethylene Glycol, the Polyethylene Glycol of methyl ether end-blocking, poly-(ethylene glycol-embedding-
Propylene glycol-embedding-ethylene glycol), polyoxyethylene ether and water-soluble liquid silicon polyethers, or water-fast medium, e.g., isopropyl lima bean
Cool acid esters, isopropyl cetylate, mineral oil, polydimethylsiloxane, fatty alcohol, and vaseline.In some embodiments,
Shared by these carriers, mass ratio is from 0 to 99.9wt%.
In some embodiments, the compositions of the present invention can also include wetting agent, buffer agent, gellant or emulsifying
Agent.Its carrier can include the aqueous buffer solution of various pH value 5.0～7.5, surfactant, organosilicon, copolyether, plants
Thing is fatty and oily, quintessence oil, hydrophilic and hydrophobic alcohol, vitamin, monoglyceride, laurate, myristinate, and cetylate is with hard
Fat acid ester.In some embodiments, the compositions of the present invention can include but not limited to, liquid, gel to be a form,
Paste, cream, Emulsion, combinations thereof and analog.
In some embodiments, the compositions of the present invention is frozen and is dried to dry powder.Freeze-dried composition can be with powder
End form uses, or is further processed into solution, cream, lotion, gel, paste, face cream, spray, foam, aerosol
Agent, film, or other preparation.
It is easy to compatible with organic solvent additionally, surface-active emulsifiers also can be added to form emulsion.Useful is organic molten
The example of agent includes, but not limited to non-irritating solvent, such as volatile silicone solvent and volatility alkane to form oil-in-water
Or water in oil emulsion, inverted emulsion, miniemulsion (nanoemulsions), microemulsion and reverse microemulsion.Non-irritating volatility
Silicone solvent includes but not limited to, the polydimethylsiloxane of low-molecular-weight, such as hexamethyl disiloxane or prestox three silica
Alkane;Low-molecular-weight annular siloxane, such as hexamethyl or the straight chain of prestox ring four, side chain or ring-type alkane, such as propane, butane
With iso-butane (pressurization lower aerosol), pentane, hexane, heptane, octane, isobutyltrimethylmethane., and their isomer, petroleum distillate,
And hexamethylene;Chlorofluorocarbons (CFCs), such as, dichlorodifluoromethane, dichlorotetra-fluoroethane and;Fluorocarbon, e.g., tetrafluoroethane, seven fluorine
Propane, 1,1-Difluoroethane, pentafluoropropane, Fluorinert PF 5070；Hydrofluoroalkane, such as 1,1,1,2-aerosol and 1,1,1,2,3,3,3-
Heptafluoro-propane, and combinations thereof etc.;Escaping gas, such as liquid carbon dioxide;Or their mixture.Some embodiment party
In case, volatile solvent can be hexamethyl disiloxane, isobutyltrimethylmethane., and their mixture.Volatile solvent can be
Hexamethyl disiloxane.In some embodiments, the quality accounting of solvent is 0 99.9wt%.
Tackifier can also be used for the present invention, and the aqueous solution that can be used for adding to α-amylase includes, but not limited to
Methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, guar gum, hydroxyl
Ethyl Guar, hydroxypropyl guar, hydroxypropyl methyl Guar, carboxymethyl guar, carboxymethyl chitosan, chitosan, locust bean gum, angle is pitched
Dish glue, xanthan gum, gellan gum, Aloe gel, scleroglucan, splits, Radix Acaciae senegalis, tamarind gum, polyvinyl alcohol, polyethylene second
Alkane, Polyethylene Glycol, polymethyl vinyl ether, carbomer and salt thereof, polyacrylic acid and salt thereof, polymethylacrylic acid and salt thereof, poly-
(2-acrylamide-2-methylpro panesulfonic acid sodium), polyacrylamide, poly-(N,N-DMAA), poly-(N-vinyl second
Amide), poly-(N-vinyl formamide), poly-(HEMA), poly-(glyceral methacrylate), poly-(N-
Vinyl pyrrolidone), NIPA and poly-(N-caprolactam), and combinations thereof.
In some embodiments, water-soluble polymer that is nonpolar and that do not degraded by amylase can serve as thickening
Agent.These viscosifier include, but are not limited to: poly(ethylene oxide)), Polyethylene Glycol, polyvinyl alcohol, and poly-(N-ethenyl pyrrolidone
Ketone).The useful other viscosifier of compositions described herein include, but are not limited to: carbomer and salt thereof, polyacrylic acid
And salt, and polymethylacrylic acid and and salt.Such viscosifier consumption is about 0.01～50.0wt%, is used for preparing various
The gel of form or paste.The usage amount of viscosifier can be 0.1～45wt%, or 0.5～25wt%, or 1 to 10wt%.
Quintessence oil can also join in preparation, as aromatic and/or as antimicrobial.Described herein group
Quintessence oil useful in compound includes, but not limited to thymol, menthol, Lignum Santali Albi, Camphora, Elettaria cardamomum (L.) Maton, Cortex Cinnamomi, jasmine, smokes clothing
Grass, Flos Pelargonii, Juniperus rigida Sieb.et Zucc., menthol, pine, Fructus Citri Limoniae, Flos Rosae Rugosae, Eucalyptus, Ding Zi, orange, Adeps Bovis seu Bubali, menthol, linalool, Herba Menthae Rotundifoliae, thin
Lotus, Radix Cymbopogonis Citrati, Fructus Citri Sarcodactylis, Herba Cymbopogonis Citrari, Cupressus funebris Endl., Semen Myristicae, PiceameyeriRehd. Et Wils., Camellia sinensis, Ilicis Purpureae (methyl salicylate), Rhizoma et radix valerianae, and combinations thereof
And analog.In some embodiments, quintessence oil can be from thymol, Oleum Santali albi, wintergreen oil, eucalyptol, Oleum Pini, and its group
Conjunction selects.In some embodiments, the quality accounting that quintessence oil can exist is from 0～5wt%.
In some embodiments, CHLOROPHYLLINE may be used for controlling abnormal smells from the patient, and provides antiinflammatory property.In some embodiments
In, the amount that CHLOROPHYLLINE can exist quality based on described compositions accounting is from 0～5wt%.
In certain embodiments, in the compositions of the present invention, non-proteolytic enzyme component can be 100wt%, or at least
99.5wt%, or at least 99wt%, or at least 95wt%, or at least 90wt%, or at least 85wt%, or at least 80wt%.?
In some embodiments, non-proteolytic enzyme component amount in the present compositions can be at least 0.001wt%, or extremely
Few 0.01wt%, or at least 0.05wt%, or at least 0.075wt%, or at least 0.1wt%, or at least 0.15wt%.
In some embodiments, the most diastatic amount can be 100wt%, at least
99.5wt%, at least 99wt%, at least 95wt%, at least 90wt%, at least 85wt%, or at least 80wt%.Implement at some
In scheme, can be 100wt%, at least 99.5wt%, at least 99wt% in the non-proteolytic diastatic amount of enzyme component, at least
95wt%, at least 90wt%, at least 85%(wt), or at least 80wt%.The amount of α-amylase can be at least 10wt%, extremely
Few 20wt%, at least 30wt%, at least 40wt%, at least 50wt%, at least 60wt%, at least 70% uncle, at least 80wt%,
At least wt90%, or 100wt%.Non-starch enzyme, non-proteolytic enzyme useful in compositions as herein described includes, but not
It is limited to, hydrolysis/cracking, and oxidation/reduction lipase, hyaluronidase, chondroitinase, heparinase, peroxidase, xylanase
Group in select enzymatic nucleic acid enzyme, phospholipase, esterase, phosphatase, different starch, maltase, glycosylase, tilactase,
At, Lactose enzyme, pectase, mannase, glucosidase, invertase, pectate lyase, reductase, oxidase, fat
Oxygenase, lignoenzyme, amylopectase, pentosanase, glucanase, arabinosidase, sulfatase, cellulase,
Hemicellulase, laccase, and mixture and analog.
The compositions of the present invention can include aqueous medium.In some embodiments, the pH scope of aqueous medium is 4.5-
8.0, or 5.5 to 7.5.In some embodiments, group water solution or gel, water-soluble polymer can be added into increase solution
Viscosity and extend the compositions time of staying on the surface of skin.
In some embodiments, the compositions of the present invention can make enhancing solution, such as gel, cream, lotion, sticks with paste
Agent, face cream, aerosol, and spray are to increase the permeability on skin.Penetration enhancer includes, but not limited to fatty acid and props up
Chain and straight chain C 6-C 18 saturated acid, unsaturated acids, such as C 14 to C 22, oleic acid, OA, linoleic acid, example
Such as acid, linolenic acid, fatty alcohol, such as saturated C8-C18 terpenes, such as d-limonene, α pinene, 3-carene, menthone, fenchone is the thinnest
Lotus ketone, piperitone, cineole, Chenopodium Oil, carvone, menthol, α terpinol, terpinene-4-alcohol, carveol, limonene oxygen
Compound, australene oxide, Pentamethylene. oxide, glyceryl triacetate, oxidizing ethyle alkyl, drives ascarid, heptane, 1,8-eucalyptole, glycerol list
Ether, glyceryl monolaurate, monoolein, isooctadecanol isostearate, isopropyl myristate, Palmic acid isopropyl
Ester, isopropyl lanolate, ketopyrrolidine, such as METHYLPYRROLIDONE, 1-ethyl-2-pyrrolidone, 5-methyl-2-pyrrole
Pyrrolidone, 1,5-dimethyl-2-Pyrrolidone, 2-Pyrrolidone-5-carboxylic acid, N-hexyl-2-Pyrrolidone, N-Lauroguadine-
Ketopyrrolidine, 1-dodecyl-2-ketone, carbamide, 1,3-diphenyl urea, dimethyl sulfoxide, decyl methyl sulfoxide, myristyl sulfone,
Cyclodextrin, with and combinations thereof.Equally valid penetration enhancer includes 1-alkyl-2-piperidones, N-dimethyl alkane amide, 1,2-
Dihydroxypropyl alkanoate such as 1,2-dihydroxy caprate, 1,2-dihydroxypropyl octanoic acid, NaTDC, trans-3-Ah
Er Ken-1-alcohol, cis-3-A Erken-1-alcohol, trans-hydroxyproline base-N-alkanamides-C-buserelin, Yi Jiqi
Combination.In some embodiments, penetration enhancers can include hydrophobic ester isopropyl myristate, Palmic acid isopropyl
Ester, and combinations thereof.
Because impaired and inflammation tissue PI, the compositions of the present invention may be included in and presents in an amount at least sufficient to stop or eradicate
The antibacterial of microorganism.Such biocide preparation includes, but not limited to antibiotic, preservative, anti-infective, antimicrobial,
Antibacterial, antifungal, antiviral agent, antiprotozoan agent, sporicide and antiparasitic.In some embodiments, sterilization
Agent is biodegradable and non-cell toxicity.Effective antibacterial includes, but not limited to biguanides, such as polyhexamethylene
Biguanide hydrochloride (PHMB), chlorhexidine and salt thereof, such as CHG (CHG), and Win-21904 and its esters.
The compositions of the present invention can need persistent on skin according to the state of an illness.Such as, in some embodiments, originally
The compositions of invention can be with contact skin about 1～48 hour, 1～24 hour, 1～12 hour, 1～8 hour, 1～4 hour, or 1
～2 hours, or 1～60 minute, 1～5 minute.In some embodiments, the method alleviating pruritus card can include periodically
Apply the present invention compositions (such as, the most every other hour, every 2 hours, every 3 hours, every 4 hours, every 6 hours, for every eight hours, etc.
Deng).The compositions removing the present invention is preferably used wiping, saline or water flushing.As required, these steps can be repeated.
Example effects
Example 1
The male at one about 60 years old age, due to skin pruritus, causes causing scratch inflammation.α-amylase (7278U/mg)
Solution with NaOH regulate pH to 7, contained α-amylase for 0.5%, wherein said alpha amylase activity is 1g/ 25000U.Pass through
Described solution wiping and is retained 10 minutes in inflammation, the skin of pruritus by non-weaving cloth, does not observe discomfort.Lead to the most again
Cross non-weaving cloth wiping several times to remove.Scratchiness alleviates for the most about 15 minutes, and makes skin keep at least 12 hours
State a less inflammation.In two days every symptom repeating this process, skin pruritus and inflammation in 12 hours be reduced and
Eliminate.
Example 2
The women at one about 70 years old age, also due to skin pruritus, causes causing scratch inflammation.Configuration is containing 0.5wt%
α-amylase, the aqueous solution of 0.15wt% chlorhexidine gluconate, and regulate pH to 7 with NaOH；Wherein said alpha amylase is lived
Property is 1g/ 25000U.By non-weaving cloth, described solution wiping and is retained 10 minutes in inflammation, the skin of pruritus, do not have
Observe discomfort.The most again by non-weaving cloth wiping several times to remove.Pruritis postpones at first time and is i.e. eased.
Two days afterwards, every symptom repeating this process, skin pruritus and inflammation in 12 hours was eliminated.
Preferred embodiment
Embodiment 1
It table 1 is the embodiment of water-soluble composition.
Table 1
| Compositions | Respective mass ratio (wt%) |
| Water/α-amylase | 99.2/0.8 |
| Water/beta amylase | 99.2/0.8 |
| Water/gamma amylase | 99.2/0.8 |
| Water/α-amylase/beta amylase | 96.60/0.34/3.16 |
| Water/α-amylase/gamma amylase | 96.60/0.34/3.16 |
Embodiment 2
It table 2 is the embodiment of the water-soluble composition containing lipase.
Table 2
| Compositions | Respective mass ratio (wt%) |
| Water/α-amylase/lipase | 99.8/0.18/0.02 |
| Water/α-amylase/lipase | 99.8/0.16/0.04 |
Embodiment 3
It table 3 is the embodiment of water-soluble composition containing sterilization component.
Table 3
| Compositions | Respective mass ratio (wt%) |
| Water/α-amylase/poly hexamethylene biguanide | 99.51/0.34/0.15 |
| Water/α-amylase/poly hexamethylene biguanide | 99.56/0.34/0.10 |
| Water/α-amylase/chlorhexidine gluconate | 99.61/0.34/0.15 |
| Water/α-amylase/chlorhexidine gluconate | 97.66/0.34/2.00 |
Embodiment 4
Table 4 is containing sterilization component and the embodiment of the water-soluble composition of thickening agent.
Table 4
| Compositions | Respective mass ratio (wt%) |
| Water/α-amylase/poly hexamethylene biguanide/PEG400 | 79.51/0.34/0.15/20 |
| Water/α-amylase/poly hexamethylene biguanide/chitosan | 99.06/0.34/0.10/0.5 |
| Water/α-amylase/chlorhexidine gluconate/PEG400 | 79.61/0.34/0.15/20 |
| Water/α-amylase/chlorhexidine gluconate/chitosan | 97.16/0.34/2.00/0.5 |
The present invention can summarize with other the concrete form without prejudice to the spirit or essential characteristics of the present invention.Therefore, no matter from
From the point of view of which point, the embodiment above of the present invention all can only be considered the description of the invention and can not limit the present invention, power
Profit claim indicates the scope of the present invention, and the scope of the present invention is not pointed out in above-mentioned explanation, therefore, is the present invention's
Any change in implication that claims are suitable and scope, is all considered as being included within the scope of the claims.
Claims (10)
1. the compositions of a novel promotion wound healing, it is characterised in that: described rush composition component comprises non-proteolytic
The proteolytic enzyme of enzyme and at maximum up to 20wt%;Described amylase is separated or base by human body, animal, plant, antibacterial, fungus
Prepare because of restructuring；
A () described non-proteolytic enzyme is made up of the amylase of at least 80wt%；
B () described non-proteolytic enzyme is at least 4:1 with the mass ratio of proteolytic enzyme.
Non-proteolytic enzyme the most according to claim 1 comprise at least 10wt%-amylase;Described non-proteolytic
Enzyme also can comprise beta amylase and gamma amylase.
At most 20% mass of non-proteolytic enzyme the most according to claim 1 is made up of one or more hydrolytic enzyme following:
Chondroitinase, hyaluronidase, lipase, glycosidase, heparanase, chondrosulphatase, amylopectase, N-acetyl Portugal
Osamine enzyme, Lactose enzyme, phospholipase, transglycosylase, esterase, thioester hydrolase, sulfatase, Sucrose Acetate esterase, nuclease, phosphorus
Acid enzyme, phosphodiesterase, mannase, mannosidase, isoamylase, lyase, inulinase, tannase, pentosanase,
Glucanase, arabinosidase, pectase, cellulase, chitinase, xylanase, at, pectase, half fiber
Element enzyme, oxidase, peroxidase, glucoseoxidase, catalase, oxidoreductase, phenol oxidase, laccase, fat
Oxygenase, isomerase, ligninase.
Compositions the most according to claim 1 further or is made up of at least one biguanides, matter shared by it
Amount is 0.01～4wt%；Described biguanides is selected from poly hexamethylene biguanide or its esters derivant composition, gluconic acid chlorine
Oneself is fixed, chlorhexidine acetate, and their combination.
Compositions the most according to claim 1 further or is made up of one or more water-soluble high-molecular substances,
Quality shared by it is 0.01～50wt%;Described water-soluble high-molecular material is selected from: methylcellulose, hydroxyethyl cellulose, hydroxypropyl
Base cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, guar gum, ethoxy Guar, hydroxypropyl guar, hydroxypropyl first
Base Guar, carboxymethyl guar, carboxymethyl chitosan, chitosan, locust bean gum, carrageenin, xanthan gum, gellan gum, Aloe gel,
Scleroglucan, splits, Radix Acaciae senegalis, tamarind gum, polyvinyl alcohol, polyethylene ethane, Polyethylene Glycol, polymethyl vinyl ether,
Carbomer and salt thereof, polyacrylic acid and salt thereof, polymethylacrylic acid and salt thereof, poly-(2-acrylamide-2-methylpro panesulfonic acid
Sodium), polyacrylamide, poly-(N,N-DMAA), poly-(N-vinyl acetamide), poly-(N-vinyl formamide),
Poly-(HEMA), poly-(glyceral methacrylate), poly-(NVP), poly-(N-isopropyl
Base acrylamide) and poly-(N-caprolactam), and combinations thereof.
Compositions the most according to claim 1 further or is made up of chelating agen, quality shared by it be 0.01%～
1wt%;. described chelating agen is selected from: ethylenediaminetetraacetic acid (EDTA), nitrilo-three acid, nitrilo three propanoic acid, diethylidene sulphur
Acid, 2-hydroxyethylethylenediaminetriacetic acid, double (2-amino-ethyl) ethylene glycol tetraacetic of O, O'-, 1,3-diaminopropanetetraacetic acid,
Double (2-hydroxybenzyl) ethylenediamine-N of N, N'-, N'-oxalic acid, ethylenediamine-N, N'-oxalic acid, ethylenediamine-N, N'-dipropionic acid,
Trien acid, ethylenediamine-N, N'-bis-(methylene phosphonic acid), iminodiacetic acid, double (2-ethoxy) the sweet ammonia of N, N-
Acid, 1，2-diaminopropane tetraacethyl, EDTMP, N-(2-ethoxy) iminodiacetic acid, di 2 ethylhexyl phosphonic acid
Ester and combinations thereof.
7. further or it is made up of adjuvant according to the compositions described in claim 1;Described adjuvant is selected from monoalkyl glycol:
1,2-PD (propylene glycol), 1,2-butanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptandiol, 1,2-ethohexadiol is (pungent
Ethylene glycol), 1,2-nonanediol, 1,2-decanediol, 1,2-hendecane, 1,2-dodecanediol, 1,2-tridecane, 1, the 2-tetradecane
Glycol, 1,2-pentadecane diols, 1,2-hexadecane diol, 1,2-heptadecane diols, 1,2-octacosanol, 2-methyl-2,4-
Pentanediol, 1,3 butylene glycol, diethylene glycol, 2,2'-ethylenedioxybis(ethanol)., double (ethoxy) ether of glycol, and combinations thereof;Described adjuvant also may be used
Selected from glycerol alkyl ether: 1-O-heptyl glycerol, 1-O-octyl glycerol, 1-O-nonyl glycerol, 1-O-caprylglyceryl, 1-O-hendecane
Base glycerol, 1-O-dodecyl glycerol, 1-O-tridecyl glycerol, 1-O-myristyl glycerol, 1-O-pentadecyl glycerol, 1-
O-cetyl (.alpha.-hexadecylglyceryl ether), 1-O-heptadecyl, 1-O-octadecyl (batilol), 1-O oleyl glycerol, shark
Oleyl alcohol, glycerol 1-(2-ethylhexyl) ether, Sensiva SC50,2-Sensiva SC50,3-(2-ethyl hexyl oxy) propane-1,2-
Glycol, 1-heptyl ether glycerol, 1-Octyl Ether glycerol, 1-decyl ethers glycerol, 1-lauryl ether glycerol, 1-tridecyl ether is sweet
Oil, 1-myristyl ether glycerol, 1-pentadecyl ether glycerol, 1-cetyl ether glycerol, 1-octadecyl ether glycerol, and it
Combination.
Compositions the most according to claim 1 or be made up of at least one medicine, medicine is selected from analgesics, anesthetis, god
Through property pain agent, and their mixture；Described medicine, its at least one medicine is selected from lignocaine, and capsaicin, stove is sweet
Granite-wash agent, benzocaine, tetracaine, prilocaine, bupivacaine, levobupivacaine, procaine, mepivacaine, according to replacing
Caine, mepivacaine, nortriptyline, the compositions selected in the group of amitriptyline, Pregabalin, diclofenac, fentanyl, add
Bar spray fourth, ketoconazole, opioid, NSAID (non-steroidal anti-inflammatory drug), salicylate, and their mixture.
Compositions the most according to claim 1, its form or be powder, aqueous solution, organic liquid is molten, silicone fluid, solidifying
Glue, hydrogel, emulsifiable paste, thin film, latex, aerosol, serosity, paste, ointment, unguentum, and foam.
Compositions the most according to claim 1 or absorption at naturally occurring or synthetic fiber, non-woven fabrics, gauze, fabric,
Hydrocolloid, alginate, gel, semipermeable membrane, on ventilated membrane, or naturally occurring or synthetic polymer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610585383.2A CN106063931A (en) | 2016-07-25 | 2016-07-25 | A kind of for treating wound pruritus and promoting the compositions of wound healing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610585383.2A CN106063931A (en) | 2016-07-25 | 2016-07-25 | A kind of for treating wound pruritus and promoting the compositions of wound healing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106063931A true CN106063931A (en) | 2016-11-02 |
Family
ID=57207632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610585383.2A Pending CN106063931A (en) | 2016-07-25 | 2016-07-25 | A kind of for treating wound pruritus and promoting the compositions of wound healing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106063931A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106860860A (en) * | 2017-03-03 | 2017-06-20 | 钱安坤 | The new opplication of polyzyme tablets |
| CN107970488A (en) * | 2018-01-08 | 2018-05-01 | 广州润虹医药科技股份有限公司 | A kind of chitin quarternary ammonium salt aquagel antiseptic dressing and preparation method thereof |
| CN108324996A (en) * | 2018-01-30 | 2018-07-27 | 深圳市盛康泰医疗器械有限公司 | A kind of body cavity imports lubricating fluid and preparation method thereof |
| CN109497093A (en) * | 2018-11-26 | 2019-03-22 | 浙江舒是生物科技有限公司 | A kind of thimerosal |
| CN109529025A (en) * | 2018-11-26 | 2019-03-29 | 浙江舒是生物科技有限公司 | A kind of medical cosmetology Special sterilizing liquid |
| CN110302415A (en) * | 2019-06-12 | 2019-10-08 | 王银梅 | A kind of preparation method of high bond strength moisture-inhibiting promoting healing wound dressing |
| CN111491666A (en) * | 2017-10-20 | 2020-08-04 | 水凝胶欧洲事务所 | Composition comprising a metal oxide and a metal oxide |
| CN115350317A (en) * | 2022-08-30 | 2022-11-18 | 振德医疗用品股份有限公司 | Wound dressing composition and preparation method thereof |
| CN115671369A (en) * | 2022-11-09 | 2023-02-03 | 华东理工大学 | Hydrogel tissue adhesive capable of being detached as required and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1816604A (en) * | 2003-06-05 | 2006-08-09 | 3M创新有限公司 | Adhesive compositions, articles incorporating same and methods of manufacture |
| CN102091097A (en) * | 2011-01-28 | 2011-06-15 | 武汉耦合医学科技有限责任公司 | Washing-free puerpera perineum medical-care gel and preparation method thereof |
| CN102300989A (en) * | 2009-01-06 | 2011-12-28 | 柯尔马克有限责任公司 | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| CN105126107A (en) * | 2015-09-21 | 2015-12-09 | 山东威高药业股份有限公司 | Liquid wound dressing |
-
2016
- 2016-07-25 CN CN201610585383.2A patent/CN106063931A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1816604A (en) * | 2003-06-05 | 2006-08-09 | 3M创新有限公司 | Adhesive compositions, articles incorporating same and methods of manufacture |
| CN102300989A (en) * | 2009-01-06 | 2011-12-28 | 柯尔马克有限责任公司 | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| CN105664144A (en) * | 2009-01-06 | 2016-06-15 | 柯尔朗恩有限责任公司 | Compositions and methods for treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| CN102091097A (en) * | 2011-01-28 | 2011-06-15 | 武汉耦合医学科技有限责任公司 | Washing-free puerpera perineum medical-care gel and preparation method thereof |
| CN105126107A (en) * | 2015-09-21 | 2015-12-09 | 山东威高药业股份有限公司 | Liquid wound dressing |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106860860A (en) * | 2017-03-03 | 2017-06-20 | 钱安坤 | The new opplication of polyzyme tablets |
| CN111491666A (en) * | 2017-10-20 | 2020-08-04 | 水凝胶欧洲事务所 | Composition comprising a metal oxide and a metal oxide |
| CN111491666B (en) * | 2017-10-20 | 2021-09-07 | 水凝胶欧洲事务所 | Topical composition for treating burns |
| CN107970488A (en) * | 2018-01-08 | 2018-05-01 | 广州润虹医药科技股份有限公司 | A kind of chitin quarternary ammonium salt aquagel antiseptic dressing and preparation method thereof |
| CN108324996A (en) * | 2018-01-30 | 2018-07-27 | 深圳市盛康泰医疗器械有限公司 | A kind of body cavity imports lubricating fluid and preparation method thereof |
| CN109497093A (en) * | 2018-11-26 | 2019-03-22 | 浙江舒是生物科技有限公司 | A kind of thimerosal |
| CN109529025A (en) * | 2018-11-26 | 2019-03-29 | 浙江舒是生物科技有限公司 | A kind of medical cosmetology Special sterilizing liquid |
| CN110302415A (en) * | 2019-06-12 | 2019-10-08 | 王银梅 | A kind of preparation method of high bond strength moisture-inhibiting promoting healing wound dressing |
| CN115350317A (en) * | 2022-08-30 | 2022-11-18 | 振德医疗用品股份有限公司 | Wound dressing composition and preparation method thereof |
| CN115350317B (en) * | 2022-08-30 | 2024-04-02 | 振德医疗用品股份有限公司 | Wound dressing composition and preparation method thereof |
| CN115671369A (en) * | 2022-11-09 | 2023-02-03 | 华东理工大学 | Hydrogel tissue adhesive capable of being detached as required and preparation method thereof |
| CN115671369B (en) * | 2022-11-09 | 2023-10-27 | 华东理工大学 | Hydrogel tissue adhesive capable of being detached as required and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106063931A (en) | A kind of for treating wound pruritus and promoting the compositions of wound healing | |
| AU2015330889B2 (en) | Compositions and kits for treating pruritus and methods of using the same | |
| CN107106663B (en) | Compositions and kits for enzymatic debridement and methods of use thereof | |
| US10238719B2 (en) | Compositions and kits for enzymatic debridement and methods of using the same | |
| Sampaio et al. | Laccase immobilization on bacterial nanocellulose membranes: Antimicrobial, kinetic and stability properties | |
| Hu et al. | Integration of cellulases into bacterial cellulose: toward bioabsorbable cellulose composites | |
| Halima | Poly (vinyl alcohol): review of its promising applications and insights into biodegradation | |
| JP5762683B2 (en) | Use of hydrolases and oxidases to dissolve biofilms in the ear | |
| US6406897B1 (en) | Modified protein, method for preparation thereof and compositions for external application containing the modified protein | |
| Wu et al. | Biocatalytic nanocomposites for combating bacterial pathogens | |
| CN103687610A (en) | Wound debridement compositions containing seaprose and methods of wound treatment using same | |
| Cavello et al. | Immobilization of a keratinolytic protease from Purpureocillium lilacinum on genipin activated-chitosan beads | |
| CN104602700A (en) | Use of seaprose to remove bacterial biofilm | |
| Buddana et al. | Mutanase enzyme from Paracoccus mutanolyticus RSP02: characterization and application as a biocontrol agent | |
| CN104411341A (en) | A smart, self-decontaminating polymer and method for inhibiting the growth of a bacteria and fungus | |
| Slovakova | Kinetic, stability, and activity of the nanoparticles-immobilized enzymes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161102 |